Daniel Allen Gold Sells 777,332 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 777,332 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $23.07, for a total value of $17,933,049.24. Following the transaction, the director owned 16,353,113 shares in the company, valued at approximately $377,266,316.91. The trade was a 4.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Daniel Allen Gold also recently made the following trade(s):

• On Tuesday, December 16th, Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock. The shares were sold at an average price of $23.04, for a total value of $21,134,177.28.
• On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.23, for a total value of $26,299,000.00.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock opened at $22.41 on Friday. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $23.47. The company’s 50 day moving average price is $20.00 and its 200-day moving average price is $15.07. The stock has a market capitalization of $15.59 billion, a price-to-earnings ratio of -40.02 and a beta of 1.22.

Wall Street Analysts Forecast Growth

ROIV has been the subject of a number of analyst reports. Leerink Partners increased their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday. Guggenheim reaffirmed a “buy” rating and set a $28.00 price target on shares of Roivant Sciences in a research report on Thursday. The Goldman Sachs Group increased their price objective on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 15th. HC Wainwright boosted their target price on Roivant Sciences from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, JPMorgan Chase & Co. upped their target price on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $25.19.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its position in shares of Roivant Sciences by 44.8% during the first quarter. PNC Financial Services Group Inc. now owns 10,248 shares of the company’s stock valued at $103,000 after purchasing an additional 3,169 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Roivant Sciences by 1.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,847,625 shares of the company’s stock valued at $28,733,000 after buying an additional 35,123 shares during the period. HighTower Advisors LLC lifted its position in Roivant Sciences by 36.4% during the first quarter. HighTower Advisors LLC now owns 13,932 shares of the company’s stock valued at $141,000 after buying an additional 3,719 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Roivant Sciences by 94.8% during the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock valued at $46,000 after buying an additional 2,233 shares in the last quarter. Finally, Candriam S.C.A. purchased a new stake in shares of Roivant Sciences in the 1st quarter worth about $276,000. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.